Q4 EPS Estimates for Opus Genetics Lowered by HC Wainwright

Key Points

• HC Wainwright cut its Q4 2026 EPS estimate for Opus Genetics to a loss of $0.16 per share from a projected loss of $0.09, while maintaining a Buy rating and $14 price target.
• Opus Genetics reported a quarterly loss of $0.46 per share, missing the consensus estimate of a $0.15 loss; revenue of $1.14 million also fell short of the $1.55 million forecast.
• Analyst sentiment is broadly positive: MarketBeat lists a “Moderate Buy” consensus rating and a $13.29 average price target, though insiders sold 673,805 shares over the past three months.

Opus Genetics, Inc. (NASDAQ:IRD - Free Report) - Investment analysts at HC Wainwright decreased their Q4 2026 earnings estimates for Opus Genetics in a report issued on Wednesday, November 11th. HC Wainwright analyst M. Caufield now expects that the company will earn ($0.16) per share for the quarter, down from their prior estimate of ($0.09). HC Wainwright currently has a "Buy" rating and a $14.00 price target on the stock. The consensus estimate for Opus Genetics' current full-year earnings is ($1.04) per share. HC Wainwright also issued estimates for Opus Genetics' FY2027 earnings at ($0.51) EPS, FY2028 earnings at ($0.28) EPS and FY2030 earnings at $0.53 EPS.

Opus Genetics (NASDAQ:IRD - Get Free Report) last posted its quarterly earnings results on Tuesday, November 10th. The company reported ($0.46) EPS for the quarter, missing the consensus estimate of ($0.15) by ($0.31). The business had revenue of $1.14 million for the quarter, compared to the consensus estimate of $1.55 million.

A number of other equities analysts also recently commented on IRD. Oppenheimer boosted their target price on shares of Opus Genetics from $10.00 to $20.00 and gave the stock an "outperform" rating in a research note on Wednesday, September 9th. TD Cowen started coverage on Opus Genetics in a report on Wednesday, July 29th. They set a "buy" rating for the company. Wall Street Zen cut Opus Genetics from a "hold" rating to a "sell" rating in a research report on Saturday, November 7th. Royal Bank Of Canada increased their price objective on Opus Genetics from $9.00 to $11.00 and gave the company an "outperform" rating in a report on Wednesday. Finally, JonesTrading increased their price objective on Opus Genetics from $10.00 to $17.00 and gave the company a "buy" rating in a report on Tuesday, October 6th. One research analyst has rated the stock with a Strong Buy rating, sixteen have given a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $13.29.

Opus Genetics Price Performance

Shares of IRD opened at $4.06 on Friday. Opus Genetics has a twelve month low of $1.70 and a twelve month high of $7.07. The firm's fifty day simple moving average is $4.50 and its 200-day simple moving average is $4.23. The firm has a market capitalization of $392.40 million, a price-to-earnings ratio of -2.60 and a beta of 0.80. The company has a current ratio of 9.65, a quick ratio of 12.19 and a debt-to-equity ratio of 0.90.

Insider Buying and Selling at Opus Genetics

In other news, Director Fighting Blindness Foundation sold 556,000 shares of the stock in a transaction dated Wednesday, September 30th. The shares were sold at an average price of $4.96, for a total transaction of $2,757,760.00. Following the completion of the sale, the director owned 3,236,171 shares in the company, valued at approximately $16,051,408.16. This represents a 14.66% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, President Benjamin R. Yerxa sold 33,189 shares of the business's stock in a transaction dated Friday, October 23rd. The shares were sold at an average price of $3.54, for a total value of $117,489.06. Following the completion of the transaction, the president owned 670,917 shares in the company, valued at $2,375,046.18. This trade represents a 4.71% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last three months, insiders have sold 673,805 shares of company stock valued at $3,213,582. Company insiders own 11.70% of the company's stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the stock. BlackRock Inc. purchased a new position in shares of Opus Genetics during the 2nd quarter worth approximately $12,809,000. Nantahala Capital Management LLC purchased a new position in Opus Genetics in the second quarter worth $12,582,185. Trails Edge Capital Partners LP purchased a new position in Opus Genetics in the second quarter worth $11,276,434. ADAR1 Capital Management LLC lifted its holdings in Opus Genetics by 4,522.5% in the first quarter. ADAR1 Capital Management LLC now owns 1,849,004 shares of the company's stock valued at $8,413,000 after acquiring an additional 1,809,004 shares during the period. Finally, Opaleye Management Inc. lifted its holdings in Opus Genetics by 0.4% in the second quarter. Opaleye Management Inc. now owns 1,125,000 shares of the company's stock valued at $4,624,000 after acquiring an additional 5,000 shares during the period. 14.97% of the stock is currently owned by hedge funds and other institutional investors.

About Opus Genetics

Opus Genetics, Inc. is a clinical-stage biotechnology company focused on developing gene therapies for inherited retinal diseases, rare conditions that can cause progressive vision loss. Its programs target specific genetic causes of these disorders, including mutations associated with Leber congenital amaurosis and retinitis pigmentosa. The company's therapies are investigational and are designed to address the underlying genetic defects rather than only manage symptoms. Opus Genetics was formed through the combination of Opus Genetics and Ocuphire Pharma; the combined company took the Opus Genetics name and began trading on Nasdaq under the symbol IRD in 2024.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.